Oramed Pharmaceuticals Reports Strong Financial Results for Third Quarter 2025

Oramed Pharmaceuticals Reports Strong Financial Results for Q3 2025

On November 17, 2025, Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a pioneer in oral delivery solutions for drugs traditionally administered via injections, reported its unaudited financial results for the nine months ending September 30, 2025. The company's latest report reveals a remarkable transformation in performance, marked by a substantial increase in net income and total assets, reflecting its successful investment strategies.

Impressive Financial Highlights

In the nine-month period of 2025, Oramed reported a pre-tax net income of $65 million, a significant turnaround from the net loss of $6.1 million recorded during the same timeframe in the previous year. This impressive growth can be attributed in large part to the company's disciplined approach to investments, including a full $100 million cash repayment from Scilex Holding Company. This timely repayment, amounting to approximately $27 million for the reported period, positions Oramed favorably for ongoing strategic pursuits.

In addition, the earnings per share have shown solid gains, with basic earnings per share standing at $1.30 and diluted earnings per share at $1.26. This performance not only increases shareholder value but also reflects the company's robust financial health, with total assets climbing by 42% from $155.3 million to $220.5 million compared to the previous year.

Strategic Investment Focus

The company attributes its enhanced financial position to realized cash returns from strategic investments and unrealized fair-value gains from equity holdings in companies like Alpha Tau Medical Ltd. Oramed CEO Nadav Kidron articulated that the disciplined investment strategy has allowed the firm to build resilience while exploring further opportunities in drug delivery technologies.

Oramed’s oral delivery technology, known as Protein Oral Delivery (POD™), aims to safeguard drug integrity and improve absorption rates, providing patients an alternative to traditional injection methods. This innovation positions Oramed at the forefront of a paradigm shift in drug delivery, making therapies more accessible and convenient for users.

Insights on Operating Expenses

While the company celebrated the financial upturn, operating expenses tell another story. Research and development (R&D) expenses have seen a slight decrease from $4.9 million to $4.4 million, which reflects the company's focused spending in line with its strategic vision. Conversely, general and administrative (GA) expenses increased from $4.3 million to $5.0 million, indicating a potential investment in operational capacity to support the growing business.

Management’s Vision for the Future

Looking ahead, Kidron shared optimism regarding Oramed's direction, emphasizing that the combination of substantial cash reserves and solid investment backings allows Oramed to explore new growth opportunities aggressively. The firm's strategic focus remains on advancing its oral drug delivery platform, which is anticipated to lead to significant market potential and patient benefits.

The FDA approval process hangs over the company's upcoming trials, and Oramed is committed to navigating these complexities while keeping investors informed. Their ability to adapt to market changes and leverage existing successes positions Oramed to emerge as a leader in the pharmaceutical sector.

Conclusion

Oramed Pharmaceuticals Inc. is poised for continued success, as demonstrated by the robust financial results for Q3 2025. The strategic repayment from Scilex, increased asset value, and ongoing investment in innovative technologies reflect Oramed's commitment to revolutionizing the pharmaceutical landscape through oral delivery systems. Investors and stakeholders alike are encouraged to watch for further developments from this trailblazing pharmaceutical company as it continues on its strategic path to enhance patient care through innovation.

For more information, please visit Oramed's official website.